Strategic Partners
	09/2007, 10/2008: Abbott Molecular. In September 2007 we signed a non-exclusive strategic collaboration and license agreement in molecular diagnostics with Abbott, a global healthcare company. Under the agreement, Abbott intends to develop an in vitro diagnostic blood test for the early detection of colorectal cancer based on our proprietary DNA methylation biomarker mSEPT9. Abbott anticipates launching a CE-marked test in Europe in 2009 followed by regulatory filing for U.S. approval in 2010. The colorectal cancer test will represent the first cancer diagnostic in the growing menu of assays on Abbott’s automated m2000 instrument, which is gaining strong acceptance in molecular diagnostics laboratories throughout the world. Abbott will conduct clinical trials and seek regulatory approval worldwide. To facilitate this, Abbott in November 2008 in an expansion of the original agreement aquired access to patient specimen collected by Epigenomics within the PRESEPT study. Under the partnership, Abbott may also evaluate some of our other proprietary biomarkers for additional cancer indications. 01/2009: Sysmex Corporation. In January 2009 we signed a strategic research and development collaboration agreement with the Japanese Sysmex Corporation. Under the terms of the agreement, Sysmex and Epigenomics will assess the suitability of Sysmex’s molecular diagnostics instrumentation for the detection of DNA methylation cancer biomarkers in blood. As a benchmark for the development of its assay system, Sysmex will use Epigenomics’ mSEPT9 Methylation Detection Assay commercially available as a research use only product. If successful, Sysmex intends to develop and commercialize initially in Japan a blood test for the early detection of colorectal cancer based on Epigenomics’ proprietary SEPT9 DNA Methylation Biomarker (mSEPT9).  12/2008: Philips. In December 2008 we entered into a collaboration and licensing agreement with Philips focusing on novel technologies and methods targeted at the diagnosis of various cancers. Under the agreement we will jointly with Philips perform feasibility studies aimed at developing an integrated and fully automated instrument platform for the diagnosis of certain cancers based on DNA methylation biomarkers. In addition, Philips obtained the option to license the required technologies and biomarkers separately or in combination for diagnostic applications. The option may be exercised upon the successful completion of the feasibility studies.
	02/2008, 02/2009: Quest Diagnostics Inc. In February 2008 we signed a non-exclusive licensing agreement for its proprietary DNA methylation biomarker mSEPT9 with Quest Diagnostics Incorporated, the leading provider of diagnostic testing, information and services in the U.S. Under the agreement, Quest Diagnostics has obtained rights to uses of the SEPT9 DNA methylation biomarker to develop a molecular-based laboratory test that can help physicians detect colorectal cancer based on a patient’s blood specimen. Quest Diagnostics plans to develop the Septin 9 DNA methylation test to act as a supplement to conventional methods of colorectal cancer screening, including colonoscopy and fecal occult blood tests (FOBTs). Quest Diagnostics is the first commercial laboratory in the U.S. to non-exclusively license the Septin 9 biomarker from us with the goal of commercializing a laboratory-developed blood test. In February 2009, Quest Diagnostics also obtained rights to uses of the GSTP1 DNA methylation biomarker (mGSTP1) to establish and commercialize a molecular-based laboratory-developed test that can help pathologists better diagnose prostate cancer based on testing of a patient’s tissue specimen.
	05/2007, 04/2005: Qiagen GmbH. In April 2005, we established a strategic collaboration with Qiagen, a leading provider of innovative technologies and products for pre- analytical sample preparation and molecular diagnostics solutions. The partnership aims at jointly developing and introducing a "gold-standard" pre-analytical solution portfolio for DNA methylation analysis. As first product based on our technology, Qiagen launched in spring 2006 the EpiTect® Bisulfite Kit for standardized conversion and cleanup of DNA for methylation analysis. Initially limited to the world wide rights for the development, manufacturing, commercialization of pre-analytical solutions containing bisulfite treatment technology and the MethylLight assay technology for research purposes, the collaboration was broadened in May 2007 by a further licensing agreement granting the exclusive worldwide rights to our sample technologies for use in applied testing and in in-vitro molecular diagnostics. We retain the rights to these technologies for use in our own or partnered development projects and for the commercialization of molecular diagnostics. As we will develop our cancer screening and specialty diagnostics tests alone or in collaboration with IVD partners, we can make use of the pre-analytical IVD solutions developed by Qiagen but can also develop pre-analytical solutions on our own or together with our IVD partners.
	06/2006: Affymetrix Inc and Epigenomics enter into a strategic partnership. Under the „Powered by Affymetrix®“ program Affymetrix has granted us non-exclusive access to Affymetrix microarray technology to develop and market microarray-based IVD tests for certain indications in oncology and further optional fields. This includes the GeneChip® System 3000Dx (GCS3000Dx), the first microarray instrumentation system for molecular diagnostic laboratories. The GCS3000Dx has already been granted regulatory clearance by the FDA and is CE marked in the European Union for IVD use in genetic testing.The first product to be developed for this system is intended to be our prostate cancer molecular classification test.
	01/2008: OncoMethylome Sciences S.A. In January 2008 we have entered into a broad technology licensing agreement with OMS. Under the terms of the agreement, OMS obtained worldwide non-exclusive rights to several of our proprietary core technologies such as its MethyLight portfolio for the sensitive and quantitative detection of DNA methylation for in vitro diagnostic product development and commercialization. Further, OMS obtained rights to HeavyMethyl® technology, plus certain microarray-based technologies for DNA methylation analysis. In return for the licenses, we will receive an up-front payment and are eligible for royalties to be paid on any eventual commercial exploitation of the technologies by OMS and any of its partners who choose to sublicense such technology.
	01/2008: DxS Ltd. In January 2008 we have entered into a strategic cross-licensing agreement with DXS Ltd.. Under the terms of the agreement, we obtain worldwide non-exclusive rights to DxS’ proprietary Scorpions® technology for R&D use and research kits, as well as an option to expand the license to the in vitro diagnostics (IVD) field. We intend to use this technology both in certain research kits as well as potentially in our cancer specialty diagnostics products. DxS in return receives an option for a worldwide non-exclusive license and further options to certain our IP covering the use of Scorpions® technology for DNA methylation applications. Both we and DxS have acquired options to sub-licensing rights for the respective technologies.
	04/2007: Cogenics, a division of Clinical Data Inc., will promote to its customers our portfolio of DNA methylation services including genome-wide DNA methylation analysis, bisulfite sequencing, and real-time PCR technologies, which are performed in our laboratories in Germany. Additionally, Cogenics can offer DNA methylation analyses in Cogenics’ laboratories in the U.S. under Good Laboratory Practice ("GLP") standard. Data generated under this standard is compliant with FDA regulations and can be used in data submissions to the FDA as part of the process of obtaining approval for a drug. Under the agreement, we will promote Cogenics’ comprehensive pharmacogenomics and molecular biology services to our potential DNA methylation biomarker development partners and customers that we serve through our clinical solutions group.
	09/2002: Roche Diagnostics and Epigenomics entered into a collaboration on the development of cancer diagnostic products. Until termination of the agreement in December 2006 (effective March 15, 2007), Epigenomics received R&D funding and milestone payments totalling EUR 30 million and discovered and validated to various levels diagnostic biomarkers for the early detection of colorectal, prostate and breast cancer. With the termination of the agreement all rights previously licensed to Roche Diagnostics reverted to Epigenomics. The programs are now available for partnering for global development, marketing and sales.
	Biomarker R&D Partnerships
	10 / 2007: Pharmion Corporation (Boulder, Co) and Epigenomics entered into a Master Services Agreement under which Epigenomics will provide DNA methylation services in connection with certain development programs that Pharmion is conducting.
	05/2007: Myriad Genetics Inc. entered into an R&D-partnership with Epigenomics to identify DNA methylation biomarkers perdicting patients' reponse to a marketed oncology drug. Within the project, Epigenomics will use its proprietary DMH technology, and OncoSignTM, a method for the rapid identification of biomarkers.
	12/2006: Centocor Inc., a US based biomedicines company and Epigenomics entered into an R&D collaboration to identify and analyze potential biomarkers for use in Centocor’s oncology program.
	08/2006: Schering AG (now Bayer-Schering-Pharma AG) and Epigenomics entered into an R&D collaboration on a biomarker study in a preclinical cancer model.
	10/2004: Biogen Idec and Epigenomics entered three different pharmacodiagnostic research collaborations over the last couple of months.
Pfizer	09/2004: Pfizer became a customer of Epigenomics
	11/2003: AstraZeneca and Epigenomics started an initial collaboration to develop DNA-methylation biomarkers for their oncology drugs, initially focussing on IRESSA.
	12/2003: Wyeth and Epigenomics initially collaborate on the development of drug response biomarkers for an anti-cancer drug developed by Wyeth in xenograft mice.
	10/2001: MethylGene and Epigenomics started a first partnership in which Epigenomics investigated gene methylation changes of patients enrolled in Phase II trials. The project was successfully completed in 2003.

Charité - Campus Benjamin Franklin, Berlin, Germany
Dr. med. Martin Rudwaleit and Prof.Dr.med. Joachim Sieper
 
Commonwealth Scientific and Industrial Research Organisation (CSIRO) 
in Campbell, Australia
Peter Molloy

Deutsches Krebsforschungszentrum (DKFZ) in Heidelberg, Germany
Dr. Jörg Hoheisel, Member of Scientific Advisory Board

Deutsches Rheuma-Forschungszentrum, Berlin, Germany
Dr. med. Jun Dong, Dr.nat. Andreas Thiel and Prof.Dr. Andreas Radbruch

Erasmus MC, Rotterdam, Netherlands
John Foekens and John Martens

Glasgow University (Beatson Laboratories), Scotland
Prof. Robert Brown

The Human Epigenome Consortium (HEC) Epigenomics has launched together with the The Wellcome Trust Sanger Institute and the Centre National de Génotypage (CNG), for uncovering the entire epigenetic information content of the human genome.

Heinrich-Heine-Universität, Düsseldorf, Germany
Prof. Wolfgang A. Schulz, PhD

Hospital La Paz, Service of Oncology, Madrid, Spain
Dr. Enrique Espinosa 

Imperial College London
R. Charles Coombes

Johns Hopkins University in Baltimore, Maryland
Prof. Andrew Feinberg, Member of Scientific Advisory Board

Massachusetts Institute of Technology, Cambridge, Massachusetts
Dr. Rudolf Jaenisch, Member of Scientific Advisory Board

Max-Planck-Institut für Molekulare Physiologie, Dortmund, Germany
Dr. Oliver Müller

Mayo Clinic in Rochester, Minnesota
David Ahlquist, MD

Muenster University Hospital, Dept. of Obstetrics and Gynecology, Germany
Dr. med. Robert R. Greb

NCI Bari in Bari, Italy
Dr. Angelo Paradiso

The Ohio State University in Athens, Ohio
Dr. Christoph Plass, Member of Scientific Advisory Board

Roy Castle International - Centre for Lung Cancer Research, Liverpool, UK
Prof. John Field

Semmelweis University, Budapest, Hungary
Bela Molnar MD PhD

Technische Universität Dresden (Universitätsklinik Carl Gustav Carus), Germany
Dr. Robert Grützmann and Prof. H.-D. Saeger

Technische Universität München, Germany
Prof. Dr. Manfred Schmitt and Dr. Nadia Harbeck

Universitätsfrauenklinik Ulm, Germany
Dr. med Wang-Gohrke

Universität des Saarlandes, Saarbrücken, Germany
Prof. Jörn Walter, Head of Genetics Department

Universitätsklinikum Eppendorf, Hamburg, Germany
Prof. Fritz Jänicke, Prof. Christoph Thomssen, Dr. Volkmar Müller and Dr. Inga Bohlmann

University of Basel 
(Stiftung Tumorbank Basel and Department of Research), Switzerland 
Prof. Dr. Urs Eppenberger and Dr. Serenella Eppenberger-Castori

University of Heidelberg, National Center for Tumor-Diseases (NCT), Germany
Multiple Myeloma Research Laboratory, Dr. Friedrich W. Cremer
Medical Department V, Prof. Hartmut Goldschmidt

University of Ljubljana, Medical Faculty - Institute of Oncology,  Slovenia
Prof. Tanja Cufer, MD, PhD

University of Regensburg, Institute of Pathology, Germany
Prof. Dr. Arndt Hartmann 

University P.J. Safarik Kosice
Faculty of Medicine, Dept. of Pharmacology, Kosice, Slovakia
Prof. Ladislav Mirossay, MD, Dr Sc.

Urology Clinics of North Texas, USA
James S. Cochran, MD

USC Norris Comprehensive Cancer Center , Los Angeles, California
Peter Jones and Peter Laird, Members of Scientific Advisory Board

Virginia Mason Medical Center/Research Center in Seattle, WA
John M. Corman MD, Director

The Wellcome Trust Sanger Institute, Cambridge, UK
Dr. Stephan Beck, Member of Scientific Advisory Board and HEC


Our consultant in Argentina, Buenos Aires, is Astrid Pavlovsky, MD.

Centro de Diagnóstico Urológico in Capital Federal, Argentina
Edgardo F. Becher, MD, PhD, Marcelo O. Borghi, MD andLuis F. Montes de Oca, MD

Halitus Instituto Médico in Buenos Aires, Argentina
Rodolfo Sergio Pasqualini MD and María Victoria Bertolino MD

Hospital de Oncología Maríe Curie in Buenos Aires, Argentina
Claudia Lebedinsky MD, Nicasio Cuneo MD and Guillermo Lerzo MD

Hospital Municipal Rivadavia in Buenos Aires, Argentina
Carlos Alberto Gaeta MD, Alicia dos Santos MD, Adriana Ferrari Cifani MD and Daniel Levy MD